Archeus Technologies, a company developing multiple differentiated radiopharmaceutical therapies, and the Wisconsin Alumni Research Foundation (WARF) have entered into a strategic collaboration to advance ART-101, a receptor-based targeting molecule, into clinical development, the company announced recently.

“Leveraging our team’s proven experience ushering new radiopharmaceutical agents from concept through clinical translation, paired with our close collaboration with (the University of Wisconsin) as a world-class radiopharmaceutical research organization, Archeus is uniquely positioned to progress ART-101 into the next stage of development,” Archeus Technologies CEO Evan Sengbusch, Ph.D., said in a statement.

According to a release, Archeus Technologies will lead Phase 1 clinical development of the ART-101 asset, with trial initiation planned for 2025.

ART-101 was discovered and developed at UW-Madison and supported by WARF through its Accelerator program.